Patients in the US with epidermal growth factor receptor mutated (EGFRm) advanced lung cancer can now receive an important new treatment option delaying disease progression by nearly nine additional months.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced last week (November 23) the submission of a type 2 extension of indication application to the European Medicines Agency (EMA).
AstraZeneca’s supplemental new drug application (sNDA) for lead lung cancer drug Tagrisso (Osimertinib) in combination with chemotherapy has been accepted and granted priority review in the US.
Small molecule drugs are carving a significant niche in lung cancer treatment, according to data and analytics company, GlobalData, and Tagrisso is well on its way to dominating the market.
The small molecule drug alectinib (Alecensa) developed by the big pharma company Roche has improved disease-free survival in patients with a specific form of non-small cell lung cancer (NSCLC) when delivered as an adjuvant therapy in a phase 3 trial.
CStone Pharmaceuticals' shares have risen after academic journal Nature Cancer published the clinical study results of its lung-cancer treatment sugemalimab.
Small molecule drug, Tagrisso (Osimertinib) taken alongside chemotherapy has showed a strong improvement in progression-free survival for patients with EGFR (epidermal growth factor receptor)-mutated advanced lung cancer, a phase 3 study has revealed.
The two pharma firms will partner to study the efficacy of Opdivo, paired with a SHP2 inhibitor, to treat non-small cell lung cancer with KRAS mutations.
The two companies will work together to evaluate the combination of SLC-391 and Keytruda in treating patients with advanced non-small cell lung cancer.
Novartis reported today that a clinical trial of the drug, known as canakinumab, when combined with chemotherapy agent, docetaxel, failed to extend the lives of patients with advanced or metastatic non-small cell lung cancer compared to just chemotherapy...
Concerto HealthAI launches model to predict survival rates in lung cancer patients in an aim to garner disease insights that could improve enrollment criteria.
The European Commission approves Pfizer’s Vizimpro monotherapy for the first-line treatment of non-small cell lung cancer, as the market is projected to grow to $26.8bn by 2025.
ATCC has released an in vitro model system for a key mechanism of invasion and metastasis in lung cancer as the company continues its efforts to provide drug discovery and development services.
Heat Biologics has announced several "necessary" but "incredibly difficult" cost cutting measures, including a workforce reduction of approximately 22%.
Avid Bioservices' expansion will double existing capacity to service both a $40m backlog and its owner Peregrine, which is hoping to commercialise its breast cancer candidate.
AstraZeneca has inked a development and commercialisation deal with Celgene for its haematology programmed cell death ligand 1 (PD-L1) candidate, MEDI4736.
Lonza and Agennix have made a tactical alliance over the Phase III production of a non-small cell lung cancer therapy in the hopes it will improve the chance of joint manufacturing after the commerical launch.
Eli Lilly, Merck & Co and Pfizer are combining resources to form the Asian Cancer Research Group (ACRG), a non-profit company which aims to accelerate research into lung and gastric cancers in Asia.
Researchers have developed a pH-responsive formulation that could be used to deliver a polyoxometalate (POM), which have broad spectrum anticancer and antiviral properties, to the colon.
Novartis has licensed a potential first-in-class vascular
disrupting agent from Antisoma in a deal worth up to $890m (€656m),
highlighting the company's increasing focus on the oncology market.
Genentech, the world's second biggest biotech company, has shown a
strong performance in the first quarter while its main rival Amgen
is trying to regain momentum after a difficult year.
Helix BioPharma and BioVectra have signed a deal for the
manufacture of Helix's new lung cancer drug for clinical trials - a
move that strengthens the already existing relationship between the
two Canadian firms.
Shares in Telik plummeted after they reported their most advanced
drug candidate failed three clinical trials, leaving analysts
asking why they did not find out sooner.
Scientists have demonstrated that a tumour suppressor gene could
actually stimulate tumour progression, which if confirmed, could
raise possibilities of using the gene as a novel prognostic
indicator of tumour aggressiveness.
US scientists think they have come up with a novel test that
indicates how a patient with early-stage lung cancer will respond
to chemotherapy, giving the opportunity to tailor treatment to the
individual.
A recent paper has emerged, which details results of a clinical
laboratory test and its ability to accurately predict drug response
in lung cancer. The test gives way to the possibility of less
invasive testing.
Scientists have found an unusual lung-cancer tumour-suppressor
gene, which was shown to restore the inactivated gene slowing the
growth of tumour cells. Its importance in cancers of the lung and
head and neck may make it a viable...
Researchers in the US have shed light on how tumours acquire
resistance to kinase inhibitors. The discovery may help explain the
acquired resistance observed in chemotherapy, which currently
blights existing cancer treatments.
Hana Biosciences announced today the clinical trial initiation of
PT-523 to evaluate this compound as a single agent in relapsed
non-small cell lung cancer (NSCLC). Lung cancer continues to carry
the poorest prognosis of cancer,...
Allos Theraputics have initiated a phase 1 study of its
investigational drug PDX (pralatrexate) that has so far proved
effective against non-small cell lung cancer (NSCLC). This
treatment has the potential to surpass Methotrexate...
Researchers from medical charity Cancer Research UK have discovered
a new gene that protects against lung cancer, according to a study
published today in the journal Proceedings of the National Academy
of Sciences..
Another drug targeting epidermal growth factor tyrosine kinase -
Roche's Tarceva, has failed to live up to early promise as a
treatment for lung cancer.
